Serotonin4 (5-HT4) receptor Agonists are putative antidepressants with a rapid onset of action

被引:270
作者
Lucas, Guillaume
Rymar, Vladimir V.
Du, Jenny
Mnie-Filali, Ouissame
Bisgaard, Christina
Manta, Stella
Lambas-Senas, Laura
Wiborg, Ove
Haddjeri, Nasser
Pineyro, Graciela
Sadikot, Abbas F.
Debonnel, Guy
机构
[1] McGill Univ, Dept Psychiat, Montreal, PQ H3A 1A1, Canada
[2] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurochirurg, Montreal, PQ H3A 2B4, Canada
[3] Univ Montreal, Ctr Rech Fernard Seguin, Montreal, PQ H1N 3V2, Canada
[4] Univ Lyon 1, Lab Neuropharmacol & Neurochim, Lyon, France
[5] Aarhus Psychiat Univ Hosp, Ctr Basic Psychiat Res, Aarhus, Denmark
[6] OWn Res Aps, Aarhus, Denmark
关键词
D O I
10.1016/j.neuron.2007.07.041
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Current antidepressants are clinically effective only after several weeks of administration. Here, we show that serotonin(4) (5-HT4) agonists reduce immobility in the forced swimming test, displaying an antidepressant potential. Moreover, a 3 day regimen with such compounds modifies rat brain parameters considered to be key markers of antidepressant action, but that are observed only after 2-3 week treatments with classical molecules: desensitization of 5-HT1A autoreceptors, increased tonus on hippocampal postsynaptic 5-HT1A receptors, and enhanced phosphorylation of the CREB protein and neurogenesis in the hippocampus. In contrast, a 3 day treatment with the SSRI citalopram remains devoid of any effect on these parameters. Finally, a 3 day regimen with the 5-HT4 agonist RS 67333 was sufficient to reduce both the hyperlocomotion induced by olfactory bulbectomy and the diminution of sucrose intake consecutive to a chronic mild stress. These findings point out 5-HT4 receptor agonists as a putative class of antidepressants with a rapid onset of action.
引用
收藏
页码:712 / 725
页数:14
相关论文
共 51 条
[11]   Assessing antidepressant activity in rodents: recent developments and future needs [J].
Cryan, JF ;
Markou, A ;
Lucki, I .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (05) :238-245
[12]   Onset of the effects of the 5-HT1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat [J].
Cryan, JF ;
McGrath, C ;
Leonard, BE ;
Norman, TR .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1999, 63 (02) :333-338
[13]   Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis [J].
David, D. J. ;
Klemenhagen, K. C. ;
Holick, K. A. ;
Saxe, M. D. ;
Mendez, I. ;
Santarelli, L. ;
Craig, D. A. ;
Zhong, H. ;
Swanson, C. J. ;
Hegde, L. G. ;
Ping, X. I. ;
Dong, D. ;
Marzabadi, M. R. ;
Gerald, C. P. ;
Hen, R. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 321 (01) :237-248
[14]   Regulation of adult neurogenesis by antidepressant treatment [J].
Duman, RS ;
Nakagawa, S ;
Malberg, J .
NEUROPSYCHOPHARMACOLOGY, 2001, 25 (06) :836-844
[15]   Novel therapeutic approaches beyond the serotonin receptor [J].
Duman, RS .
BIOLOGICAL PSYCHIATRY, 1998, 44 (05) :324-335
[16]   PHARMACOLOGICAL CHARACTERIZATION OF 2 NOVEL AND POTENT 5-HT4 RECEPTOR AGONISTS, RS-67333 AND RS-67506, IN-VITRO AND IN-VIVO [J].
EGLEN, RM ;
BONHAUS, DW ;
JOHNSON, LG ;
LEUNG, E ;
CLARK, RD .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 115 (08) :1387-1392
[17]   Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission:: an in vivo electrophysiological study in rat brain [J].
El Mansari, M ;
Sánchez, C ;
Chouvet, G ;
Renaud, B ;
Haddjeri, N .
NEUROPSYCHOPHARMACOLOGY, 2005, 30 (07) :1269-1277
[18]   5-HT4 receptor-mediated modulation of 5-HT release in the rat hippocampus in vivo [J].
Ge, JA ;
Barnes, NM .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 117 (07) :1475-1480
[19]  
Haddjeri N, 1998, J NEUROSCI, V18, P10150
[20]   In-vivo modulation of central 5-hydroxy-tryptamine (5-HT1A) receptor-mediated responses by the cholinergic system [J].
Haddjeri, N ;
Faure, C ;
Lucas, G ;
Mnie-Filali, O ;
Chouvet, G ;
Astier, B ;
Renaud, B ;
Blier, P ;
Debonnel, G .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 (04) :391-399